Charles River Laboratories International (CRL) EPS (Weighted Average and Diluted): 2009-2025
Historic EPS (Weighted Average and Diluted) for Charles River Laboratories International (CRL) over the last 17 years, with Sep 2025 value amounting to $1.10.
- Charles River Laboratories International's EPS (Weighted Average and Diluted) fell 17.29% to $1.10 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.51, marking a year-over-year decrease of 118.85%. This contributed to the annual value of $0.20 for FY2024, which is 97.83% down from last year.
- According to the latest figures from Q3 2025, Charles River Laboratories International's EPS (Weighted Average and Diluted) is $1.10, which was up 3.77% from $1.06 recorded in Q2 2025.
- Charles River Laboratories International's 5-year EPS (Weighted Average and Diluted) high stood at $3.65 for Q4 2022, and its period low was -$4.17 during Q4 2024.
- For the 3-year period, Charles River Laboratories International's EPS (Weighted Average and Diluted) averaged around $1.10, with its median value being $1.33 (2024).
- Per our database at Business Quant, Charles River Laboratories International's EPS (Weighted Average and Diluted) skyrocketed by 50.83% in 2022 and then slumped by 214.56% in 2024.
- Quarterly analysis of 5 years shows Charles River Laboratories International's EPS (Weighted Average and Diluted) stood at $2.67 in 2021, then soared by 36.70% to $3.65 in 2022, then dropped by 0.27% to $3.64 in 2023, then tumbled by 214.56% to -$4.17 in 2024, then decreased by 17.29% to $1.10 in 2025.
- Its EPS (Weighted Average and Diluted) stands at $1.10 for Q3 2025, versus $1.06 for Q2 2025 and $0.50 for Q1 2025.